DermTech, Inc.

DermTech, Inc., formerly associated with SPAC ticker CNAC, is a precision dermatology company focused on non-invasive genomic skin diagnostics, operating in the healthcare and life sciences sector. The company completed its SPAC business combination in 2019 and filed this Form 8-K on May 27, 2020, reflecting ongoing post-merger public company reporting obligations with the SEC. DermTech's flagship product is a non-invasive adhesive skin patch used to detect genomic markers associated with melanoma, positioning it within the high-growth molecular diagnostics space. The combined company subsequently traded under the ticker DMTK on Nasdaq. For complete filing history, transaction details, and real-time SPAC data on DermTech and hundreds of other deals, sign up for full access at SpacDesk.